

Supplementary Table 3. Virological, serological, and biochemical responses by baseline HBeAg status (PPS)

	HBeAg-positive patients (n=84)			HBeAg-negative patients (n=60)		
	BSV-BSV (n=47)	TDF-BSV (n=37)	P-value	BSV-BSV (n=30)	TDF-BSV (n=30)	P-value
HBV DNA <69 IU/mL	43 (91.5)	33 (89.2)	0.73	30 (100.0)	30 (100.0)	-
HBV DNA <20 IU/mL	39 (83.0)	30 (81.1)	0.82	30 (100.0)	29 (96.7)	1.00
HBeAg loss*	14/47 (29.8)	14/37 (37.8)	0.44	-	-	-
HBeAg seroconversion*	3/47 (6.4)	5/37 (13.5)	0.29	-	-	-
HBsAg loss [†]	0/47 (0.0)	1/37 (2.7)	0.45	0/30 (0.0)	0/30 (0.0)	-
HBsAg seroconversion [†]	0/47 (0.0)	1/37 (2.7)	0.45	0/30 (0.0)	0/30 (0.0)	-
ALT normalization [‡]	40 (85.1)	34 (91.9)	0.50	29 (96.7)	28 (93.3)	1.00

Values are presented as n/N (%) or number (%).

P-value: Pearson's chi-square test/Fisher's exact test.

HBeAg, hepatitis B envelope antigen; BSV, besifovir dipivoxil maleate; TDF, tenofovir disoproxil fumarate; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; ALT, alanine aminotransferase.

*Among HBeAg-seropositive patients at baseline.

[†]Among HBsAg-seropositive patients at baseline.

[‡]Among patients with baseline ALT levels above the central laboratory normal range (0–41 U/L for males and 0–33 U/L for females).